Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The CDC and WHO have deemed the COVID-19 virus a global pandemic of unprecedented severity in
modern times. In 2019, this novel Coronavirus (COVID-19) emerged from the Asian continent and
has now caused upwards of 1million deaths and over 6 million infections globally. Currently,
the estimated global economic impact is over 5 Trillion dollars. Understanding the host
response to pathogens, specifically the cellular and humoral responses, has played an
important role in new non-antibiotic therapies. Bismuth subsalicylate (Pepto-Bismol) has a
potential role in the clearance and/or recurrence of enteric viral infections.